-
1 Comment
Malaysian Genomics Resource Centre Bhd is currently in a long term uptrend where the price is trading 47.6% above its 200 day moving average.
From a valuation standpoint, the stock is 2112.0% more expensive than other stocks from the Other sector with a price to sales ratio of 142.1.
Malaysian Genomics Resource Centre Bhd's total revenue sank by 97.3% to $136K since the same quarter in the previous year.
Its net income has dropped by 106.4% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 51.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Malaysian Genomics Resource Centre Bhd gets an overall score of 2/5.
| ISIN | MYQ0155OO000 |
|---|---|
| Exchange | KLSE |
| CurrencyCode | MYR |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | 27M |
|---|---|
| Target Price | 0.8 |
| PE Ratio | None |
| Beta | 0.55 |
| Dividend Yield | None |
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. Its flagship product, Dtect genetic screening tests which inspects DNA for markers associated with genetic variations that influence various biological processes. The company also offers genome sequencing services for humans, animals, plants, and microbes and other living organisms; transcriptome sequencing; and metagenomics and metatranscriptomics. In addition, it provides genome analysis services, including bioinformatics, trait analysis, and trio sequencing; genetic screening services, such as Dtect and Origene genetic screening test; and CAR T-cell immunotherapy treatment for different types of cancer. Further, it is involved in dealing in capital markets and derivative instruments; acting as general merchants; business relating to life sciences/cell lab and by products; and distribution of healthcare products, beauty products, and precision medicine. Additionally, the company provides system developments and information technology comprising software and hardware, as well as other human health services and general medical services. The company has research and development collaborations with Universiti Sains Malaysia; De Cell Berhad; Twsitcode Technologies Sdn Bhd; Kumpulan Medic Iman Sdn Bhd; Innoquest Pathology Sdn Bhd; and Kumpulan Perubatan Penawar Sdn Bhd and Hospotal Penawar Sdn Bhd. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0155.KLSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
